I just saw this press release. Hopefully his experience can make a real difference here at Acadia...anyone else have opinions on the potential of ACAD longterm? TIA
"“Jim brings extensive commercial experience to our Board as we continue our transition to an integrated pharmaceutical company,” said Leslie L. Iversen, Ph.D., Chairman of ACADIA’s Board of Directors. “Over the course of his career, Jim has successfully launched and commercialized major products in multiple therapeutic areas and built market-leading global franchises. His deep knowledge and expertise are welcome as we deliver on our vision of building a leading CNS company dedicated to improving the lives of patients through innovative medicines.”
Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. During his tenure, he was instrumental in re-accelerating the launch of Jakafi® and driving sustained growth. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for ten years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®.
Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®. He currently serves on the Board of Directors of Chimerix Inc. Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo, The State University of New York.
Market Data 
Markets 
AI
